The FDA has granted accelerated approval to linvoseltamab-gcpt, a BCMA-directed bispecific T-cell engager, offering a new option for patients with heavily pretreated relapsed or refractory multiple myeloma....
A new analysis from Western Washington investigators suggests that adverse financial events at diagnosis may delay treatment initiation for patients with hematologic malignancies, highlighting a potential...
